Physician profile
Rupal N Chavda
NPI 1760799894
$2,178.87
in general payments reported to CMS, 2019-2025
21 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $93.77 · 2021: $47.03 · 2022: $404 · 2023: $690 · 2024: $401 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $630.53 | 2019-2025 | Rinvoq |
| Amgen INC. | $331.05 | 2019-2025 | Otezla, Enbrel, Amjevita |
| Pfizer INC. | $239.58 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $144.11 | 2022-2024 | Saphnelo |
| Horizon Therapeutics Plc | $115.05 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $110.48 | 2019-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $104.55 | 2019-2024 | |
| Genentech USA, INC. | $97.92 | 2019-2024 | Actemra |
| Janssen Biotech, INC. | $91.39 | 2022-2025 | Tremfya |
| Glaxosmithkline, LLC. | $47.56 | 2019 | |
| Merck Sharp & Dohme LLC | $47.14 | 2019 | |
| Ucb, INC. | $40.09 | 2022-2024 | Bimzelx |
| Mallinckrodt Enterprises LLC | $30.18 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.49 | 2024 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $22.84 | 2024 | Orencia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $19.82 | 2019 | |
| Novo Nordisk INC | $18.47 | 2025 | Rybelsus, Ozempic |
| Celgene Corporation | $17.62 | 2019 | |
| Sandoz INC. | $17.62 | 2023 | Hyrimoz |
| Bioventus LLC | $15.66 | 2024 | Durolane |
| Genzyme Corporation | $13.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Chavda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.